EU approves Otsuka's long-acting HAE drug Dawnzera An EMA nod for Otsuka's Dawnzera offers EU patients with HAE a drug that can be self-administered by patients with up to eight weeks between doses.

#hereditaryangioedema #Otsuka #Ionis #Dawnzera #regulatoryapproval #Rarediseases #pharmanews #HAEdrug #Dawnzera #antisenseoligonucleotidebasedplasmaprekallikreininhibitor #PKKinhibitor #plasmaprekallikreininhibitor #PKK #EMA #HAEpatients #clinicaltrials #RNAtargetedtherapy
zurl.co/Zw7sM

NICE finalises support for CSL's HAE therapy Andembry CSL Behring's Andembry can be used to prevent recurrent attacks of HAE by the NHS, following finalised guidance from reimbursement authority NICE

#NICE #CSL #HAEtherapy #Andembry #garadacimab #PharmaNews #CSLBehring #hereditaryangioedema #HAE #NHS #NICEguidance #NICETAG #FactorXIIainhibitor #HAEpatients #raregeneticdisorder #MHRA #VANGUARDstudy #HAEattacks #HAEUK #AngelaMetcalfe #HAEprevention #EduardoCabas
pharmaphorum.com/news/nice-fi...

CSL receives positive opinion for garadacimab in hereditary angioedema - PharmaTimes New treatment could revolutionise care for HAE patients

#CSL #CSLBehring #garadacimab #hereditaryangioedema #HAE #HAEpatients #EMA #CHMP #factorXIIainhibitor #HAEattacks #CHMPdecision #HAEattacks #HAEattackprevention #Phase3clinicaltrial #VANGUARDclinicaltrial #openlabelextensionstudy
pharmatimes.com/news/csl-rec...